

December 9, 2016

The logo features the word "DCAT" in blue, "TOP" in orange with an upward-pointing arrow, and "Industry NEWS" in blue.

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

The Patheon logo includes the tagline "A HEALTHIER WORLD. DELIVERED." below the brand name.**Executive insights. Delivered.**[Learn more](#)

1. Mylan Plans Restructuring and Cuts in Global Workforce

Mylan has announced restructuring plans to streamline operations globally. Mylan anticipates the restructuring to impact less than 10% of its global workforce. It is currently developing the details of the cost-reduction initiatives, including workforce actions and other potential restructuring activities, and further details will be disclosed as initiatives are finalized. [Read More](#)

2. AstraZeneca Plans Job Cuts in US Commercial Business

AstraZeneca has said it will eliminate 700 positions across its US commercial business, including its North American commercial headquarters, as part of its ongoing restructuring. The impacted positions include some field-based sales, field-based non-sales roles, and roughly 80 positions from existing vacancies, as well as a reduction in discretionary spend. [Read More](#)

3. Amgen, Allergan File Avastin Biosimilar With EMA

Amgen and Allergan have submitted an application with the European Medicines Agency for a biosimilar candidate of Avastin (bevacizumab), Roche's blockbuster anti-cancer biologic, which had 2015 sales of CHF 6.68 billion (\$6.56) billion. This follows an earlier filing with the FDA for a biosimilar of bevacizumab. [Read More](#)

4. Novartis, Kite Pharma Plan Regulatory Filings for CAR T Therapies

Novartis and Kite Pharma are filing separate applications seeking regulatory approval for their respective chimeric antigen receptor T-cell cancer (CAR T) therapies. The filings follow announced plans by the companies for the manufacturing of these products. [Read More](#)

5. Sanofi, JHL Biotech in Biosimilars Pact for China

Sanofi has formed an alliance with JHL Biotech, a Taiwan-based biopharmaceutical company, to develop and commercialize biosimilars in China. Under the agreement, Sanofi will invest \$80 million in newly issued JHL shares and make an upfront payment of \$21 million to acquire exclusive rights for a proposed biosimilar of rituximab, a blockbuster biologic of Roche, as well as options to certain JHL pipeline products. [Read More](#)

6. AstraZeneca Completes \$330-Million Divestment of Respiratory Drug to J&J

AstraZeneca has completed its previously announced agreement to divest the rights to Rhinocort Aqua

(budesonide) nasal spray outside the US to Cilag GmbH International, an affiliate of Johnson & Johnson. The product is indicated for allergic and non-allergic rhinitis and for treating nasal polyps.

[Read More](#)

7. [Shire Moves Forward with \\$400 Million Biomanufacturing Expansion](#)

Shire is moving forward with its \$400 million biomanufacturing expansion at Piercetown, County Meath in Ireland after gaining formal planning permission from local authorities. The site will supply both clinical and commercial-scale products and is expected to be operational by mid-2019. [Read More](#)

8. [Teva Appoints New President and CEO of Generics Group](#)

Teva Pharmaceutical Industries has named Dipankar Bhattacharjee president and CEO, Global Generic Medicines Group. He succeeds Sigurdur Olafsson, who will step down from his role and remain active with the company until he retires at the end of the 2017 first quarter. [Read More](#)

9. [Lonza Sells Belgium Peptides Biz to PolyPeptides Group](#)

Lonza is selling its peptide business operations in Braine-l'Alleud, Belgium to the PolyPeptide Group, a Torrance, California-headquartered contract manufacturing organization. [Read More](#)

10. [Celgene to Acquire Acetylon as New Startup is Spun Out](#)

Celgene has agreed to acquire Acetylon Pharmaceuticals, boosting its portfolio in oncology, neurodegeneration, and autoimmune diseases. Prior to the acquisition, Acetylon will spin out a new company, Regenacy Pharmaceuticals, LLC, to develop gene-therapy-based drug candidates. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org